See more : PT Panca Anugrah Wisesa Tbk (MGLV.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Hemogenyx Pharmaceuticals Plc (HEMO.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hemogenyx Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Nepra Foods Inc. (NPRA.CN) Income Statement Analysis – Financial Results
- Chuo Gyorui Co., Ltd. (8030.T) Income Statement Analysis – Financial Results
- Astec LifeSciences Limited (ASTEC.NS) Income Statement Analysis – Financial Results
- Huisheng International Holdings Limited (1340.HK) Income Statement Analysis – Financial Results
- Tronox Holdings plc (TROX) Income Statement Analysis – Financial Results
Hemogenyx Pharmaceuticals Plc (HEMO.L)
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85K | 0.00 |
| Cost of Revenue | 645.68K | 2.60M | 283.65K | 350.72K | 421.82K | 348.27K | 100.48K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -645.68K | -2.60M | -283.65K | -350.72K | -421.82K | -348.27K | -100.48K | 0.00 | 6.85K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 90.63K | 402.94 | 37.58 | 83.66 | 21.25 | 57.65K | 14.05K | 1.62K | 0.00 | 0.00 |
| General & Administrative | 4.91M | 942.35K | 1.40M | 623.84K | 429.07K | 402.98K | 390.66K | 331.59K | 174.30K | 6.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.22K | 33.51K | 14.63K | 19.49K | 80.40K | 2.40K | 0.00 |
| SG&A | 4.91M | 942.35K | 1.40M | 628.06K | 462.58K | 417.61K | 410.16K | 411.99K | 176.70K | 6.27K |
| Other Expenses | 1.46M | 1.99M | 1.15M | 1.24M | 786.72K | 91.36K | 101.14K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.47M | 2.93M | 2.55M | 1.87M | 1.25M | 1.26M | 690.69K | 411.99K | 176.70K | 6.27K |
| Cost & Expenses | 6.47M | 5.53M | 2.83M | 2.22M | 1.67M | 1.61M | 791.17K | 411.99K | 176.70K | 6.27K |
| Interest Income | 85.34K | 10.60K | 17.96K | 3.37K | 14.19K | 4.37K | 0.00 | 0.00 | 11.02K | 0.00 |
| Interest Expense | 315.99K | 33.00 | 2.60M | 33.24K | 31.33K | 1.78K | 10.74K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 645.68K | 564.07K | 126.34K | 106.75K | 94.73K | 51.81K | 33.61K | 11.87K | 169.86K | 0.00 |
| EBITDA | -5.73M | -3.42M | -2.39M | -1.96M | -1.36M | -1.63M | -837.06K | -447.15K | -0.59 | -6.27K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -160.97% | 0.00% |
| Operating Income | -6.47M | 4.00M | -2.70M | -2.15M | -1.68M | -1.62M | -820.98K | -519.90K | -169.86K | -6.27K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,481.32% | 0.00% |
| Total Other Income/Expenses | -230.65K | 10.57K | -2.41M | 55.36K | 195.99K | 27.16K | -1.54M | -60.88K | -11.02K | 0.00 |
| Income Before Tax | -6.70M | -3.99M | -5.11M | -2.10M | -1.49M | -1.52M | -2.36M | -519.90K | -180.88K | -6.27K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| Income Tax Expense | 0.00 | 361.16K | 2.41M | 20.44K | -35.00K | -43.75K | -49.70K | 183.74K | -11.02K | 0.00 |
| Net Income | -6.69M | -4.35M | -7.52M | -2.12M | -1.45M | -1.48M | -2.36M | -519.90K | -180.88K | -6.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| EPS | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 65.17M | 12.66M | 64.90M |
| Weighted Avg Shares Out (Dil) | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 65.17M | 12.66M | 64.90M |
Source: https://incomestatements.info
Category: Stock Reports